Release of StoneChecker 20.12

3 December 2020

IQ-AI Ltd

("IQ-AI" or the "Company")

StoneChecker's New Release Contains Workflow Enhancements

IQ-AI today announces the release of StoneChecker (SC) application 20.12. This release encompasses workflow enhancements for retrieving computed tomography (CT) datasets as well as streamlined reporting of the application's output. IQ-AI is confident that this release of SC Software is now positioned for widespread clinical adoption.

Streamlining and automating workflows has been IQ-AI's primary focus throughout 2020; an appropriate response to the current needs of clinical and research communities where almost one-half of all radiologists report feelings of burnout. IQ-AI has developed key technologies to tackle this growing concern. Of significance is an artificial intelligence (AI) model that accelerated IQ-AI's "gad-free" initiative, which is currently undergoing validation testing, and will likely dovetail into processing stroke data.

Other technology developments undertaken in 2020 build upon the core algorithms of IQ-AI. Inherent system variabilities continue to hamstring magnetic resonance (MR) imaging, such as magnet inhomogeneities, imaging artifacts, suboptimal signal-to-noise ratios, etc. IQ-AI continues to counter these issues by incorporating pre-processing technologies which ensure the quantitative integrity and appearance of processed data.

Intelligently applying technology that efficiently and automatically presents clinicians with validated and proven output will remain a strategic initiative for IQ-AI, laying a pathway for a busy and exciting 2021.

Trevor Brown CEO commented, "We believe retaining and developing StoneChecker will prove to be the right decision for IQAI shareholders, and the developmental leaps made by IB in 2020 point to a very exciting 2021". 

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.